
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences is a clinical-stage biotechnology company with a positive outlook due to their gene circuit platform and promising pipeline. The company's current clinical trial for SENTI-202, a blood cancer treatment, has shown impressive results with the use of the "Donor X" phenotype, which is found in approximately 50% of adult donors and does not present any operational constraints. However, there are risks associated with financing and manufacturing that could impact future progress and share dilution for investors. Overall, the potential for success in the gene therapy space and the company's current progress make Senti Biosciences a promising investment opportunity.
Bears say
Senti Biosciences is a clinical stage biotechnology company focused on developing cell and gene therapies for incurable diseases through its proprietary gene circuit platform. However, while its lead candidate, SENTI-202, has shown promising results in a heavily pretreated AML population, there are still uncertainties around the regulatory approval and commercial potential of such therapies. Additionally, the company's need for additional financing and potential competition from other players in the cell therapy space pose risks to future profitability.
This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares